View Item 

Show simple item record

Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor
dc.contributor.authorSwiecicki, Paul L.
dc.contributor.authorBellile, Emily
dc.contributor.authorCasper, Keith
dc.contributor.authorChinn, Steven Bennett
dc.contributor.authorDragovic, Aleksandar F.
dc.contributor.authorJolly, Shruti
dc.contributor.authorKupfer, Robbi
dc.contributor.authorMalloy, Kelly M.
dc.contributor.authorMierzwa, Michelle Lynn
dc.contributor.authorShuman, Andrew G.
dc.contributor.authorSpector, Matthew E.
dc.contributor.authorSrinivasan, Ashok
dc.contributor.authorStucken, Chaz
dc.contributor.authorBradford, Carol Rossier
dc.contributor.authorEisbruch, Avraham
dc.contributor.authorCarey, Thomas E.
dc.contributor.authorPrince, Mark E.
dc.contributor.authorWolf, Gregory T.
dc.contributor.authorWorden, Francis P.
dc.date.accessioned2022-07-05T21:00:26Z
dc.date.available2023-08-05 17:00:24en
dc.date.available2022-07-05T21:00:26Z
dc.date.issued2022-07
dc.identifier.citationSwiecicki, Paul L.; Bellile, Emily; Casper, Keith; Chinn, Steven Bennett; Dragovic, Aleksandar F.; Jolly, Shruti; Kupfer, Robbi; Malloy, Kelly M.; Mierzwa, Michelle Lynn; Shuman, Andrew G.; Spector, Matthew E.; Srinivasan, Ashok; Stucken, Chaz; Bradford, Carol Rossier; Eisbruch, Avraham; Carey, Thomas E.; Prince, Mark E.; Wolf, Gregory T.; Worden, Francis P. (2022). "Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor." Head & Neck 44(7): 1509-1519.
dc.identifier.issn1043-3074
dc.identifier.issn1097-0347
dc.identifier.urihttps://hdl.handle.net/2027.42/172949
dc.description.abstractBackgroundSingle cycle induction chemotherapy (IC) with platinum and 5-flurouracil (PF) and treatment based on clinical response predicts organ preservation in laryngeal cancer. Other agents offer intriguing alternatives with potentially increased ease of administration, reduced risk for severe toxicities, and increased platinum sensitivity.MethodsWe report the results of a phase II bioselection trial in advanced resectable laryngeal cancer utilizing an IC regimen of two cycles of platinum plus docetaxel (TP) with a Bcl-2 inhibitor. The primary endpoint was organ preservation rate at 12 weeks post chemoradiation.ResultsFifty-four patients were enrolled. Response to IC was 72%. The organ preservation rate was 59% with a laryngectomy free survival of 46%. Induction related grade ≥3 toxicities were observed in 56% of patients with two grade 5 events.ConclusionsTwo cycles of TP IC plus a Bcl-2 inhibitor did not improve laryngeal preservation compared to a single cycle of PF.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.otherlaryngeal cancer
dc.subject.otherchemoradiation
dc.subject.otherinduction chemotherapy
dc.subject.otherneoadjuvant chemotherapy
dc.subject.otherorgan preservation
dc.titleRandomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172949/1/hed27043_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172949/2/hed27043.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172949/3/hed27043-sup-0001-TableS1.pdf
dc.identifier.doi10.1002/hed.27043
dc.identifier.sourceHead & Neck
dc.identifier.citedreferenceCosetti M, Yu GP, Schantz SP. Five-year survival rates and time trends of laryngeal cancer in the US population. Arch Otolaryngol Head Neck Surg. 2008; 134: 370 - 379.
dc.identifier.citedreferenceWoolen S, Virkud A, Hadjiiski L, et al. Prediction of disease free survival in laryngeal and hypopharyngeal cancers using CT perfusion and radiomic features: a pilot study. Tomography. 2021; 7: 10 - 19.
dc.identifier.citedreferenceSwiecicki PL, Bellile E, Sacco AG, et al. A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016; 34: 481 - 489.
dc.identifier.citedreferenceDepartment of Veterans Affairs Laryngeal Cancer Study G, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991; 324: 1685 - 1690.
dc.identifier.citedreferenceStein MN, Goodin S, Gounder M, et al. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020; 38: 855 - 865.
dc.identifier.citedreferenceSonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012; 23: 1803 - 1808.
dc.identifier.citedreferenceForastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091 - 2098.
dc.identifier.citedreferenceSinger S, Danker H, Guntinas-Lichius O, et al. Quality of life before and after total laryngectomy: results of a multicenter prospective cohort study. Head Neck. 2014; 36: 359 - 368.
dc.identifier.citedreferenceForastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018; 36: 1143 - 1169.
dc.identifier.citedreferenceBauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL. Mol Cancer Ther. 2005; 4: 1096 - 1104.
dc.identifier.citedreferenceKumar B, Cordell KG, D’Silva N, et al. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008; 134: 363 - 369.
dc.identifier.citedreferenceBauer JA, Kumar B, Cordell KG, et al. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 69: S106 - S108.
dc.identifier.citedreferenceGibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the eastern cooperative oncology group. J Clin Oncol. 2005; 23: 3562 - 3567.
dc.identifier.citedreferenceWolf GT, Bellile E, Eisbruch A, et al. Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 2017; 143: 355 - 366.
dc.identifier.citedreferenceUrba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol. 2006; 24: 593 - 598.
dc.identifier.citedreferenceEisbruch A, Thornton AF, Urba S, et al. Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. J Clin Oncol. 1996; 14: 2322 - 2330.
dc.identifier.citedreferenceSchuman AD, Birkeland AC, Farlow JL, et al. Predictors of stricture and swallowing function following salvage laryngectomy. Laryngoscope. 2021; 131: 1229 - 1234.
dc.identifier.citedreferenceMeulemans J, Debacker J, Demarsin H, et al. Oncologic outcomes after salvage laryngectomy for squamous cell carcinoma of the larynx and hypopharynx: a multicenter retrospective cohort study. Ann Surg Oncol. 2021; 28: 1751 - 1761.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
hed27043_am.pdf
Size:
429.9KB
Format:
PDF
View/Open
Name:
hed27043.pdf
Size:
1.389MB
Format:
PDF
View/Open
Name:
hed27043-sup-0001-TableS1.pdf
Size:
53.92KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.